«KINTARO Cells®» are multipotent bone marrow-derived mesenchymal stem cells that have the ability to differentiate into cells of various types. Unlike autologous cells derived from adipose tissue, which are taken from the patients to be transplanted back into themselves, we use allogeneic stem cells obtained from young, healthy donors in their 20s.

Autologous cells are still widely used in Japan; however, the mainstream use of cell therapy has already begun to shift to allogeneic cells. Currently, we are expanding our research, development, and manufacturing under the brand «KINTARO Cells®», where our products are cultured using Japan’s advanced culture technology and patented manufacturing.

Only 1 in 100,000 cells in bone marrow fluid are discovered and extracted, making mesenchymal stem cells derived from bone marrow quite rare. Multipotent stem cells «KINTARO Cells®» are extracted by using advanced biotechnology and successful proliferation through patented culture technology.

The highest number of bone marrow mesenchymal stem cells is found in the human body at the moment of birth. However, the number decreases with age: from 100% at birth to 10% during the teenage years, 4% during a person’s 30s, 2.5% during a person’s 50s, and 0.5% during a person’s 80s. «KINTARO Cells®» are multipotent stem cells that have the effect of supplementing stem cells in an aging body and regenerating cells and organs. «KINTARO Cells®» are obtained and cultured from young, healthy donors in their 20s.

In addition, «KINTARO Cells®» have the CD34- marker that eliminates risks of transferring any disease from a donor. The culture fluid that is approved by the American Food and Drug Administration (FDA) meets the requirements of Good Manufacturing Practice. This shows that the cultivation is carried out in accordance with international standards.